MX343589B - Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida. - Google Patents

Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida.

Info

Publication number
MX343589B
MX343589B MX2013014630A MX2013014630A MX343589B MX 343589 B MX343589 B MX 343589B MX 2013014630 A MX2013014630 A MX 2013014630A MX 2013014630 A MX2013014630 A MX 2013014630A MX 343589 B MX343589 B MX 343589B
Authority
MX
Mexico
Prior art keywords
leukotoxin
microbicide
inflammatory agent
new anti
subject
Prior art date
Application number
MX2013014630A
Other languages
English (en)
Other versions
MX2013014630A (es
Inventor
J Torres Victor
Unutmaz Derya
Alonzo Francis Iii
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Publication of MX2013014630A publication Critical patent/MX2013014630A/es
Publication of MX343589B publication Critical patent/MX343589B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente invención se refiere a métodos para prevenir o tratar la infección por el virus de inmunodeficiencia humana (VIH), afecciones inflamatorias y la enfermedad de injerto contra huésped (GVHD) en un sujeto. Las composiciones terapéuticas de la presente invención comprenden proteínas o polipéptidos de leucocidina E (LuKe) y/o D. La invención también referida a métodos para tratar infección por Staphylococcus aureus administrando una composición que comprende un antagonista de CCR5 o cualquier molécula que bloquea la interacción de LuKe/D con células CCR5' en una cantidad eficaz para tratar la infección por S. aureus en el sujeto.
MX2013014630A 2011-06-19 2012-06-19 Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida. MX343589B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498606P 2011-06-19 2011-06-19
PCT/US2012/043182 WO2012177660A2 (en) 2011-06-19 2012-06-19 Leukotoxin e/d as a new anti-inflammatory agent and microbicide

Publications (2)

Publication Number Publication Date
MX2013014630A MX2013014630A (es) 2014-05-14
MX343589B true MX343589B (es) 2016-11-11

Family

ID=47423178

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014630A MX343589B (es) 2011-06-19 2012-06-19 Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida.

Country Status (14)

Country Link
US (3) US8846609B2 (es)
EP (2) EP2720754B1 (es)
JP (1) JP6093760B2 (es)
KR (1) KR20140071318A (es)
CN (1) CN103764228B (es)
AU (1) AU2012273125B2 (es)
BR (1) BR112013032911A2 (es)
CA (1) CA2839558A1 (es)
CL (1) CL2013003651A1 (es)
ES (1) ES2609817T3 (es)
MX (1) MX343589B (es)
MY (1) MY165115A (es)
RU (1) RU2609650C2 (es)
WO (1) WO2012177660A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ764564A (en) * 2011-06-19 2022-10-28 Univ New York Methods of treating and preventing staphylococcus aureus infections and associated conditions
CN104428000A (zh) * 2012-05-02 2015-03-18 纽约大学 治疗和预防金黄色葡萄球菌感染和相关病状的方法
US10301378B2 (en) 2013-06-18 2019-05-28 New York University Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets
CN104744451A (zh) * 2013-12-30 2015-07-01 中国科学院上海药物研究所 一种1-(3-氨基丙基)取代环状胺类化合物、其制备方法、药物组合物及用途
BR112017021779A2 (pt) * 2015-04-17 2018-07-10 Arsanis Biosciences Gmbh ?uma preparação combinada de anticorpos anti-staphylococcus aureus?
EP3313412A4 (en) * 2015-06-23 2019-01-16 CytoDyn Inc. CCL5 LIGAND BINDING INHIBITION TO CCR5 RECEPTOR AND CCR5 / CCL5 AXIS SIGNALING MODIFICATION IN INFLAMMATION, CANCER, AUTOIMMUNIT DISEASE OR OTHER CONDITIONS

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1121135B1 (en) 1998-09-14 2009-01-28 Nabi Biopharmaceuticals Compositions of beta-glucans and specific immunoglobulins
US20070010509A1 (en) 1999-12-08 2007-01-11 Tatsuki Shiota Cycloamine ccr5 receptor antagonists
KR20030032916A (ko) * 2000-02-09 2003-04-26 휴먼 게놈 사이언시즈, 인크. Ｃｃｒ5에 대한 항체
US6476062B2 (en) 2000-03-30 2002-11-05 Schering Corporation Chemokine receptor antagonists
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
US20030171563A1 (en) 2001-05-18 2003-09-11 Mcnamara Peter J. Regulators of bacterial virulence factor expression
AU2003247772A1 (en) 2002-06-27 2004-01-19 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
EP1593680A4 (en) * 2003-02-07 2008-05-07 Takeda Pharmaceutical PYRIDINE DERIVATIVES WITH CONDENSED RING, PROCESS FOR THEIR PREPARATION AND USE
IL157398A0 (en) * 2003-08-14 2004-02-19 Hadasit Med Res Service Pharmaceutical compositions comprising ccr5 antagonists
US7622125B2 (en) * 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
EP2305294B1 (en) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei
ATE484500T1 (de) 2005-01-06 2010-10-15 Schering Corp Synthese von ccr5 rezeptor antagonisten
WO2011047011A2 (en) 2009-10-13 2011-04-21 University Of Medicine And Dentistry Of New Jersey Treatment and diagnosis of inflammatory disorders
WO2007062150A2 (en) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Leukotoxin compositions and therapeutic methods
US20110143992A1 (en) * 2006-02-13 2011-06-16 Dennis Taub Methods and Compositions Related to GHS-R Antagonists
CN101466376A (zh) * 2006-06-12 2009-06-24 辉瑞产品公司 用于提高免疫重建并治疗hiv患者的机会感染的ccr5拮抗剂
CN102743747A (zh) 2006-06-12 2012-10-24 葛兰素史密斯克蓝生物品公司 α-毒素在治疗和预防葡萄球菌感染上的用途
JP2008013447A (ja) 2006-07-03 2008-01-24 Juntendo 毒素検出方法
WO2008016006A1 (en) * 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
EP2066674B1 (en) 2006-09-18 2010-06-30 F.Hoffmann-La Roche Ag Octahydropyrrolo [3, 4-c] pyrrole derivatives and their use as antiviral agents
EP2120928A2 (en) * 2007-02-15 2009-11-25 Pfizer Limited Pharmaceutical compositions and methods for ccr5 antagonists
DK2510947T3 (en) 2009-04-14 2016-03-21 Glaxosmithkline Biolog Sa Compositions for Immunization against Staphylococcus aureus.
US8409584B2 (en) 2009-05-05 2013-04-02 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins

Also Published As

Publication number Publication date
KR20140071318A (ko) 2014-06-11
RU2609650C2 (ru) 2017-02-02
US20130039885A1 (en) 2013-02-14
US20150056163A1 (en) 2015-02-26
NZ619942A (en) 2016-02-26
US20170224768A1 (en) 2017-08-10
EP2720754A2 (en) 2014-04-23
AU2012273125B2 (en) 2017-05-25
EP2720754B1 (en) 2016-10-19
CN103764228A (zh) 2014-04-30
WO2012177660A2 (en) 2012-12-27
AU2012273125A1 (en) 2014-01-16
JP2014520150A (ja) 2014-08-21
ES2609817T3 (es) 2017-04-24
US8846609B2 (en) 2014-09-30
EP3135339A1 (en) 2017-03-01
US9480726B2 (en) 2016-11-01
RU2014101489A (ru) 2015-07-27
MY165115A (en) 2018-02-28
CN103764228B (zh) 2017-09-08
CL2013003651A1 (es) 2014-09-26
WO2012177660A3 (en) 2013-02-21
JP6093760B2 (ja) 2017-03-08
CA2839558A1 (en) 2012-12-27
BR112013032911A2 (pt) 2017-01-24
MX2013014630A (es) 2014-05-14
EP2720754A4 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
EA201590342A1 (ru) Лечение иммуноопосредуемых и воспалительных заболеваний
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12014502524B1 (en) Carboxylic acid compounds
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
EA201500582A1 (ru) Тройные фунгицидные смеси
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MX344530B (es) Compuestos de benceno substituido.
MX369385B (es) Productos para cicatrizar heridas tisulares.
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MX343589B (es) Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida.
GB2511685A (en) Muscarinic m1 receptor agonists
MX2013004061A (es) Analogos de ciclosporina.
EA201492016A1 (ru) C-17 бициклические амины тритерпеноидов с ингибиторной активностью созревания вич
MX2013004062A (es) Analogos de ciclosporina.
MX2015007065A (es) Metodo y composiciones para tratar diarrea asociada con vih.
WO2014205127A3 (en) Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
IN2013MU01244A (es)
IN2013MU01250A (es)
IN2013MU01245A (es)
IN2013MU01246A (es)
IN2013MU01247A (es)

Legal Events

Date Code Title Description
FG Grant or registration